Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit

Logo

SHANGHAI and HONG KONG, Aug. 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Company has been invited to participate in the Evercore 2nd China Biotech Summit, where it presented multiple key R&D highlights during a fireside chat. At the event, the Company presented updated clinical data for ATG–022 (CLDN18.2 antibody–drug conjugate [ADC]). Regarding T–cell engager (TCE) technologies, beyond its previously disclosed proprietary AnTenGager® TCE platform, the Company showcased the TriGager™ TCE platform and multiple TCE functional modules for the first time. This further demonstrates the Company's complete TCE engineering technology toolbox and illustrates the technical principles behind the TriGager™ TCE platform. In addition, the Company also introduced ATG–207, a first–in–class αCD3-TGF-β bifunctional fusion protein.

Logo

Recommended for you